Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial

Shimizu, Toshimasa; Kawashiri, Shin-ya; Morimoto, Shimpei; Kawazoe, Yurika; Kuroda, Shohei; Kawasaki, Rina; Ito, Yasuko; Kiya, Rieko; Sato, Shuntaro; Yamamoto, Hiroshi; Kawakami, Atsushi

doi:10.1186/s13063-023-07176-5

Trials

Article metrics
Last updated: Fri, 26 Apr 2024 15:26:57 Z

Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial

Access & Citations

1968

Article Accesses
1

Web of Science
1

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1745-6215

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com